ArticlePloS one2018
Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04306419 (Observational Trial on Cytokine Adsorption in Sepsis), which is not on this map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Trial on Cytokine Adsorption in Sepsis
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- The role of hemoadsorption in cardiac surgery - a systematic review.BMC cardiovascular disorders · 2024Pooled it
- Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta-analysis of randomized controlled trials.Acta anaesthesiologica Scandinavica · 2022Pooled it
- Hemoperfusion and blood purification strategies in patients with COVID-19: A systematic review.Artificial organs · 2021Pooled it
- Cytokine hemoadsorption with CytoSorb® in patients with sepsis: a systematic review and meta-analysis.Critical care sciencePooled it
- Trial
- Trial
- Extracellular Vesicles as Mediators of Endothelial and Tubular Injury in Cardiac Surgery-Associated Acute Kidney Injury.Biomedicines · 2026Review
- Impact of CytoSorb Hemoadsorption Therapy on Cost-Effectiveness and Length of Stay in Critical Care Patients: A Preliminary Study from a Swiss High-Volume Center.Healthcare (Basel, Switzerland) · 2026Article
- Effects of hemoadsorption on plasma catecholamine levels: an in vitro study.Scientific reports · 2026Article
- Antibiotics and Other Drugs Removal by the CytoSorbAntibiotics (Basel, Switzerland) · 2026Review
- The Effects of CytoSorb in Critically Ill Adult Patients on Vasopressor Support: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Cytokines Adsorption During Ex Situ Machine Perfusion of Liver Grafts from Elderly Donors: A Pilot, Prospective, Randomized Study.Life (Basel, Switzerland) · 2026Article
- A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.Frontiers in immunology · 2026Article
- The International, Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: Interim Results in Patients with Septic Shock.Annals of intensive care · 2026Article
- Extracorporeal therapies for post-liver transplant recipient: The road less traveled.World journal of transplantation · 2025Review
- Extracorporeal Blood Purification with CytoSorb® Hemoadsorption in Valve Surgery for Infective Endocarditis: A Case Series.The American journal of case reports · 2025Article
- Hemadsorption with CytoSorb®: focus on the latest experiences in cardiac surgery patients.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Review
- From critical care to organ preservation: the potential role of hemadsorption in transplantation-a narrative review.Hepatobiliary surgery and nutrition · 2025Review
- Extracorporeal Cytokine Adsorption in Sepsis: Current Evidence and Future Perspectives.Biomedicines · 2025Review
- Hemoadsorption in septic shock - PRO.Intensive care medicine · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. In sepsis and septic shock, pathogen-associated molecular pattern molecules (PAMPS), such as bacterial exotoxins, cause direct cellular damage and/or trigger an immune response in the host often leading to excessive cytokine production, a maladaptive systemic inflammatory response syndrome response (SIRS), and tissue damage that releases DAMPs, such as activated complement and HMGB-1, into the bloodstream causing further organ injury. Cytokine reduction using extracorporeal blood filtration has been correlated with improvement in survival and clinical outcomes in experimental studies and clinical reports, but the ability of this technology to reduce a broader range of inflammatory mediators has not been well-described. This study quantifies the size-selective adsorption of a wide range of sepsis-related inflammatory bacterial and fungal PAMPs, DAMPs and cytokines, in a single compartment, in vitro whole blood recirculation system. MEASUREMENTS AND MAIN
resultsPurified proteins were added to whole blood at clinically relevant concentrations and recirculated through a device filled with CytoSorb® hemoadsorbent polymer beads (CytoSorbents Corporation, USA) or control (no bead) device in vitro. Except for the TNF-α trimer, hemoadsorption through porous polymer bead devices reduced the levels of a broad spectrum of cytokines, DAMPS, PAMPS and mycotoxins by more than 50 percent.
conclusionsThis study demonstrates that CytoSorb® hemoadsorbent polymer beads efficiently remove a broad spectrum of toxic PAMPS and DAMPS from blood providing an additional means of reducing the uncontrolled inflammatory cascade that contributes to a maladaptive SIRS response, organ dysfunction and death in patients with a broad range of life-threatening inflammatory conditions such as sepsis, toxic shock syndrome, necrotizing fasciitis, and other severe inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.